New long-term data on Genentech’s groundbreaking drug for multiple sclerosis, the first approved for the most aggressive form of the condition, shows it has continued to work — and that patients who started the drug earlier got the most benefit.

Genentech will be presenting the data, which covers years’ worth of open-label extension studies of the drug, at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis in Berlin, which begins Wednesday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy